Skip to main content (Press Enter).
Login
Skip auxiliary navigation (Press Enter).
Contact Us
ISCT in the News
Media
Career Center
Donate
ISCT Community
Skip main navigation (Press Enter).
Toggle navigation
Search Options
Annual & Regional Meetings
Annual Meetings
ISCT 2024 Vancouver
ISCT 2025 New Orleans
ISCT 2026 Dublin
Regional Meetings
ISCT Europe 2024
ISCT ANZ 2024
Membership
Workforce Development
About ISCT Institute of Training and Development
ISCT Institute of Training and Development Training Programs
Clinical Cell & Gene Therapy Training Programs
Harmonized Laboratory & Manufacturing Practices Training Programs
Standards Training Programs
Career Development Programs
Program Catalogue
ISCT Learning Center
Accreditation
Publications
Cytotherapy - ISCT Journal
Regulatory Initiatives
Regulatory Report
ISCT-AABB GTP Interpretative Tool
FDA Cell Therapy Liaison Meeting - CTLM
Telegraft Member Newsletter
Annual Report
Education
Laboratory Life Line
Patient Resources
Webinars
Events Calendar
ISCT 2025 New Orleans
ISCT 2026 Dublin
About ISCT
About Us
Staff
Leadership
Committees
Partner Organizations
2024 Elections
2024 Major Awards
Contact Us
Career Center
Contact Us
Blogs
Access the June 17 ISCT Webinar on 'The End of the FDA Enforcement Discretion Period and its Implications'
By
Felix Grignon
posted
Jun 21, 2021 12:11
0
Recommend
The end of the
FDA Enforcement Discretion Period
for certain human cell, tissue, and tissue-based products (HCT/Ps), including regenerative medicine therapies, marks a new chapter in the regulation of stem cell clinics in the United States.
The objective of this webinar is to provide public information that a) summarizes the three years of the FDA Enforcement Discretion Period and reviews its impact on clinics and the market, and b) fosters a discussion among attending and impacted stakeholders on initiatives and strategies to be pursued post Enforcement Discretion Period.
The webinar took place on June 17, 2021 and a recording is accessible through the following link:
https://www.isct-unprovencellulartherapies.org/the-end-of-the-fda-enforcement-discretion-period-and-its-implications/
#News
0 comments
19 views
Permalink
Most Recent Posts
Committee Spotlight: Process Development & Manufacturing Sub-Committee, Process Automation Analytics ...
Feb 13, 2024 10:41
Blog Entry
From the Editor: Guiding Potency Assurance in Cell Therapy from All Angles
Feb 13, 2024 10:24
Blog Entry
ISCT Leads Global Scientific Consortia to Respond to Recent FDA Report on Risk of T-Cell Malignancy in ...
Jan 09, 2024 17:19
Blog Entry
More News From ISCT
Press Releases
Powered by Higher Logic